Current Reviews in Clinical and Experimental Pharmacology
Scope & Guideline
Fostering Collaboration in Pharmacological Research
Introduction
Aims and Scopes
- Clinical Pharmacology and Therapeutics:
The journal focuses on the effects, safety, and efficacy of drugs in clinical settings, providing insights into therapeutic interventions and management of various diseases. - Translational Research:
It emphasizes the importance of translating laboratory findings into clinical applications, exploring new therapeutic targets, drug mechanisms, and treatment strategies. - Systematic Reviews and Meta-Analyses:
The journal frequently publishes systematic reviews and meta-analyses to synthesize evidence regarding pharmacological treatments and interventions, aiding in clinical decision-making. - Emerging Therapies and Novel Drug Development:
Current Reviews highlights innovative drug formulations, repurposing existing medications, and the exploration of alternative therapies such as natural compounds and nutraceuticals. - Preclinical and Experimental Models:
The journal discusses preclinical studies and experimental models that are crucial for understanding drug mechanisms and testing new therapeutic approaches.
Trending and Emerging
- Integrative and Multidisciplinary Approaches:
There is a growing trend towards integrative studies that combine pharmacology with other disciplines, such as genomics, proteomics, and systems biology, to enhance therapeutic efficacy. - Natural Products and Herbal Medicine:
Recent publications have increasingly highlighted the role of natural products and herbal compounds in pharmacotherapy, reflecting a renewed interest in alternative and complementary medicines. - Patient-Centric Research:
Emerging themes emphasize the importance of patient perspectives, adherence, and individualized treatment strategies, aligning with the broader movement towards patient-centered care. - Advanced Therapeutic Modalities:
The journal is increasingly publishing research on advanced therapeutic modalities, such as gene therapy, cell therapy, and nanotechnology, indicating a shift towards innovative treatment options. - Drug Repurposing and Safety Profiles:
There is a notable increase in studies focusing on drug repurposing strategies and the safety profiles of existing medications, particularly in the context of emerging health crises like the COVID-19 pandemic.
Declining or Waning
- Traditional Pharmacotherapy:
There appears to be a waning interest in traditional pharmacotherapy approaches without innovative angles, as more research is focused on novel therapies and drug repurposing. - Single-Agent Drug Studies:
Research that solely focuses on the efficacy of single-agent drugs without considering combination therapies or multi-target approaches is becoming less common. - Historical Reviews of Established Drugs:
While historical reviews of established drugs were once prevalent, there is now a shift towards investigating new compounds and their potential applications. - Pharmacokinetics in Stable Populations:
Studies focusing on pharmacokinetics in stable populations are declining as the journal shifts towards more dynamic and complex patient populations, including those with comorbidities. - Basic Science without Clinical Relevance:
Research that emphasizes basic science without a clear pathway to clinical application is becoming less favored in favor of studies with direct clinical implications.
Similar Journals
International Journal of Pharmacology
Innovating Insights in Drug Development and SafetyWelcome to the International Journal of Pharmacology, a key publication in the field of pharmacology, published by ASIAN NETWORK SCIENTIFIC INFORMATION (ANSINET). Since its inception in 2006, this journal has provided a vital platform for researchers and professionals to disseminate their findings and insights in pharmacology, toxicology, and pharmaceutics. Despite recent discontinuation in Scopus coverage, the journal's dedication to fostering scientific dialogue continues to attract contributions from esteemed scholars globally. With an **ISSN of 1811-7775** and **E-ISSN of 1812-5700**, the journal seeks to bridge the gap between laboratory research and clinical application, promoting a deeper understanding of drug actions and interactions. Although it operates under traditional access options, the relevance of its published studies to ongoing pharmacological research remains significant.
JOURNAL OF CLINICAL PHARMACOLOGY
Transforming Clinical Practice with Cutting-Edge ResearchWelcome to the Journal of Clinical Pharmacology, an esteemed publication in the field of pharmacology and medical pharmacology, published by Wiley. Since its inception in 1973, this journal has been at the forefront of disseminating innovative research findings and comprehensive reviews that enhance our understanding of drug therapies and their clinical applications. With an impact factor that reflects its strong reputation and a Scopus ranking placing it in the 64th percentile among 272 journals in medical pharmacology, the journal stands as a critical resource for researchers, healthcare professionals, and students alike. Although currently not an Open Access journal, it provides invaluable insights into therapeutic drug use and safety, the pharmacokinetics of drugs, and the development of new therapeutic strategies. The journal's commitment to advancing the field through high-quality, peer-reviewed articles ensures it remains a vital asset in the continuously evolving landscape of clinical pharmacology.
ANNALS OF PHARMACOTHERAPY
Exploring Innovations in Therapeutic ScienceANNALS OF PHARMACOTHERAPY, published by SAGE PUBLICATIONS INC, is a leading journal in the realm of pharmacology and therapeutic science, dedicated to advancing research, clinical practice, and education in the field of medicine. With a solid history dating back to its first publication in 1981, this journal offers a platform for high-quality research articles that explore the latest innovations and methodologies in pharmacotherapy. Although it operates under a subscription-based model, the journal maintains a robust academic reputation, reflected in its Scopus ranking in the 68th percentile within the category of Medicine - Pharmacology (Rank #85/272). The impact factor is continually evolving, as is the scope, which encompasses a diverse range of topics from clinical trials to the therapeutic applications of newly-developed drugs. Researchers, professionals, and students alike will find valuable insights and cutting-edge research in the ANNALS OF PHARMACOTHERAPY, making it an essential resource for anyone engaged in the field of pharmacology.
DARU-Journal of Pharmaceutical Sciences
Exploring the forefront of pharmacology and toxicology.DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.
FUNDAMENTAL & CLINICAL PHARMACOLOGY
Pioneering insights in pharmacology since 1987.FUNDAMENTAL & CLINICAL PHARMACOLOGY is a distinguished journal dedicated to advancing the fields of pharmacology and clinical medicine. Published by WILEY, this journal serves as a pivotal platform for researchers, healthcare professionals, and students alike to disseminate innovative research findings and clinical applications. With an impressive history spanning from 1987 to 2024, it has consistently maintained its relevance in the scientific community, evidenced by its Q2 quartile ranking in both Pharmacology and Pharmacology (medical) categories for 2023. The journal's diverse publication range, which includes original research articles, reviews, and clinical studies, helps bridge the gap between fundamental research and practical application in healthcare settings. Although it does not offer open access, its rigorous peer-review process ensures that published content meets the highest scholarly standards, making it a vital resource for those aiming to stay at the forefront of pharmacological sciences.
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
Exploring Innovative Research for Clinical ExcellenceCLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.
Acta Pharmaceutica Sinica B
Connecting Researchers for Groundbreaking DiscoveriesActa Pharmaceutica Sinica B is a prestigious open access journal that has been setting the standard in the field of pharmacology, toxicology, and pharmaceutics since its establishment in 2011. Published by the Institute of Materia Medica, Chinese Academy of Medical Sciences, the journal serves as a vital platform for researchers, professionals, and students seeking to disseminate innovative findings in drug development, pharmaceutical sciences, and therapeutic applications. With an impressive impact factor reflecting its high academic quality, Acta Pharmaceutica Sinica B has achieved Q1 status in the category of Pharmacology, Toxicology and Pharmaceutics as of 2023, ranking #1 out of 80 journals in General Pharmacology. This journal not only focuses on the latest advancements in drug research and formulation but also emphasizes interdisciplinary approaches, fostering collaborations that span various scientific domains. The accessible nature of the journal, combined with its rigorous peer-review process, ensures that crucial insights and breakthroughs reach a global audience swiftly and effectively. For those looking to stay at the forefront of pharmaceutical research, Acta Pharmaceutica Sinica B is an indispensable resource.
Pharmaceutical Sciences
Exploring innovative solutions in pharmaceutical sciences.Pharmaceutical Sciences, an esteemed journal published by Tabriz University of Medical Sciences, Faculty of Pharmacy, serves as a crucial platform for the dissemination of pioneering research in the fields of pharmaceutical science, pharmacology, and toxicology. With an impact factor reflective of its substantial contribution to the scientific community, this open access journal has been accessible since 2012, ensuring that researchers, professionals, and students worldwide can engage with its rich content. Located in Iran, it has continually evolved, covering research from 2009 to 2024, and boasts impressive rankings in multiple Scopus categories, including Q3 in Pharmaceutical Science and Q2 in Pharmacology, Toxicology and Pharmaceutics. By bridging gaps between scientific inquiry and practical applications, Pharmaceutical Sciences is dedicated to advancing pharmaceutical knowledge and promoting innovative practices that address significant health challenges.
BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
Navigating the Complexities of Drug Action and ToxicityBASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.
Therapeutics and Clinical Risk Management
Empowering clinical excellence with rigorous risk management insights.Therapeutics and Clinical Risk Management is a pioneering journal published by DOVE MEDICAL PRESS LTD, dedicated to advancing the fields of medication safety, pharmacology, and clinical risk management through rigorous research and comprehensive reviews. With an impact factor that demonstrates its significance within various disciplines, this Open Access journal has been instrumental since its inception in 2006, promoting the dissemination of knowledge to a global audience without barriers. With its reach spanning categories such as Pharmacology, Medicine, and Chemical Health and Safety, it champions innovative practices and risk assessment methodologies. The journal is recognized in the Q2 quartile for multiple related categories and excels in rank within its field, highlighting its influential contributions to safety and therapeutic practices. By prioritizing the sharing of impactful research, Therapeutics and Clinical Risk Management serves as an indispensable resource for researchers, professionals, and students aiming to enhance clinical outcomes and mitigate risks in therapeutic paradigms.